Healthcare / Syndicated loan facility

Paris, November 18^th, 2021

Rapid diagnostic test manufacturer BIOSYNEX, advised by Natixis Partners Debt Advisory, has announced the signing on November 15, 2021 of a syndicated loan facility for a maximum amount of €109 million.

 

This transaction was arranged by Caisse d’Epargne Grand-Est Europe, advised by De Gaulle Fleurance & Associés.

 

Through this financing, BIOSYNEX plans to secure the Group’s general needs and pursue its external acquisitions with the ambition of becoming the European leader in the field of rapid POC (“Point Of Care”) diagnostics.

 

These acquisitions are intended to build up a portfolio of synergistic and complementary technologies in molecular biology and in point-of-care. In addition, the Group intends to accelerate its international development through the consolidation of its distributors and the creation of new subsidiaries.

De Gaulle Fleurance & Associés (May Jarjour, Partner, and Vahan Guevorkian, Lawyer) advised La Caisse d’Epargne Grand-Est Europe (Mireille Maury) on this transaction.